From: AIDS and the pancreas in the HAART era: a cross sectional study
Degree | ||||||
---|---|---|---|---|---|---|
Variable | Year | Absent | Light | Moderate | Intense | p* |
Decreased zimogen granula | 1995 | 52 (47,7%) | 52 (47,7%) | 5 (4,6%) | 0 (0,0%) | < 0,001 |
2010 | 1 (5,0%) | 9 (45,0%) | 6 (30,0%) | 4 (20,0%) | ||
Dysplasia-like | 1995 | 35 (32,1%) | 48 (44,0%) | 19 (17,4%) | 7 (6,4%) | < 0,001 |
2010 | 19 (95,0%) | 0 (0,0%) | 0 (0,0%) | 1 (5,0%) | ||
Atrophy | 1995 | 44 (40,4%) | 45 (41,3%) | 17 (15,6%) | 3 (2,8%) | 0,017 |
2010 | 2 (10,0%) | 13 (65,0%) | 3 (15,0%) | 2 (10,0%) | ||
Steatosis | 1995 | 36 (33,0%) | 43 (39,5%) | 23 (21,1%) | 7 (6,4%) | 0,689 |
2010 | 7 (35,0%) | 7 (35,0%) | 6 (30,0%) | 0 (0,0%) | ||
Inflammation | 1995 | 59 (54,1%) | 39 (35,8%) | 7 (6,4%) | 4 (3,7%) | 0,673 |
2010 | 12 (60,0%) | 5 (25,0%) | 2 (10,0%) | 1 (5,0%) | ||
Haemorrhage | 1995 | 78 (71,6%) | 26 (23,9%) | 4 (3,7%) | 1 (0,9%) | 0,921 |
2010 | 14 (70,0%) | 5 (25,0%) | 1 (5,0%) | 0 (0,0%) | ||
Fibrosis | 1995 | 67 (61,5%) | 22 (20,2%) | 16 (14,7%) | 4 (3,7%) | 0,173 |
2010 | 8 (40,0%) | 6 (30,0%) | 6 (30,0%) | 0 (0,0%) | ||
Stoppers | 1995 | 107 (98,2%) | 2 (1,8%) | 0 (0,0%) | 0 (0,0%) | 0,026 |
2010 | 17 (85,0%) | 3 (15,0%) | 0 (0,0%) | 0 (0,0%) | ||
Necrosis | 1995 | 91 (83,5%) | 18 (16,5%) | 0 (0,0%) | 0 (0,0%) | 0,057 |
2010 | 18 (90,0%) | 1 (5,0%) | 1 (5,0%) | 0 (0,0%) | ||
Apoptosis | 1995 | 109 (100,0%) | 0 (0,0%) | 0 (0,0%) | 0 (0,0%) | < 0,001 |
2010 | 4 (20,0%) | 8 (40,0%) | 7 (35,0%) | 1 (5,0%) | ||
Increased Islets | 2010 1995 | 8 (40,0%) 109 (100,0%) | 9 (45,0%) 0 (0,0%) | 3 (15,0%)0 (0,0%) | 0 (0,0%) 0 (0,0%) | < 0,001 |
Islets with | 1995 | 109 (100,0%) | 0 (0,0%) | 0 (0,0%) | 0 (0,0%) | 0,023 |
dysplasia-like changes | 2010 | 18 (90,0%) | 2 (10,0%) | 0 (0,0%) | 0 (0,0%) |